Jubilant Pharmova Ltd. is a pharmaceutical company based in India with a risk rating score of 29.7, indicating a medium risk level. The company operates in various segments including Radiopharma, Allergy Immunotherapy, Sterile Injectables, Generics, Contract Research, Development, and Proprietary Novel Drugs. With a strong focus on ESG principles, Jubilant Pharmova generates its highest revenue from the Radiopharma segment. The company primarily caters to the Americas and Europe markets.